Nonalcoholic fatty chiropa chirwere (NAFLD) chirwere chinowanzoitika. Kuti unzwisise zviri nani kubatana pakati peNAFLD uye hepatocellular carcinoma (HCC) ngozi, vatsvakurudzi veBaylor College yeMishonga vakaita chidzidzo chikuru cheRetrospective chakabudiswa mu "Gastroenterology".
Muchidzidzo ichi, chikwata chetsvakurudzo chakadzidza mapoka kubva kuVeterans Health Administration uye ndokutevera kwemakore angangoita gumi nerimwe. Chidzidzo chacho chaisanganisira varwere ve11 vanozivikanwa kuti vane NAFLD uye 296,707 varwere vasina NAFLD. Pakati pevarwere veNAFLD, 296,707 vane HCC, uye njodzi yavo yekuvandudza HCC yakanyanya kudarika avo vasina NAFLD.
Dr. Fasiha Kanwal, purofesa uye mukuru wemishonga, uye vashandi vakawana kuti NAFLD varwere vane chiropa chechiropa vane huwandu hwepamusoro hweHCC gore negore. Ngozi yeHCC inowedzera nezera, uye vakwegura vekuSpain vane chiropa chechiropa ndeyeHCC High-risk groups.
“This study provides valuable and powerful information on which of the millions of NAFLD patients are at risk for HCC. This information is an important step forward in our understanding of the disease. For researchers, clinical Doctors and patients have important reference value, ” said Dr. Hashem EI-Serag, professor of gastroenterology at Baylor Medicine and senior author of the paper . Moreover, the results of this study also provide guidance for monitoring and risk adjustment for people at increased risk of gomarara rechiropa, such as patients with cirrhosis or diabetes.
